Alzheimers disease and psychiatric polygenic risk are disease-specific and independent of plasma biomarkers in a real-world young-onset dementia cohort.

Background: Young onset dementia is frequently misdiagnosed, particularly where neurodegenerative and primary psychiatric disorders (PPD) overlap. Plasma biomarkers measure current pathology, whereas polygenic risk scores (PRS) capture lifelong genetic risk. Whether PRS derived from late-onset and population samples transfer to young-onset presentations, and how they relate to plasma biomarkers, is unknown. Methods: We studied 687 participants of European ancestry from the Markers in Neuropsychiatric Disorders (MiND) Study, a prospective young-onset neuropsychiatry cohort: 195 healthy controls

This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program: especially if you are pregnant, nursing, taking medication, or managing a health condition.